Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bergenin is a naturally occurring C-glycoside of 4-O-methyl gallic acid, classified as a trihydroxybenzoic acid glycoside. It is found in several plant species, including *Bergenia ciliata*, *Bergenia ligulata*, and others. Traditionally used in Ayurvedic, Chinese, and Unani medicine systems, bergenin exhibits a wide range of biological activities. Its mechanisms include potent immunomodulatory effects and antioxidant activity through free radical scavenging. Pharmacologically, it demonstrates anti-inflammatory (via cyclooxygenase-2 inhibition and modulation of Th1/Th2 cytokine production), hepatoprotective, neuroprotective, gastroprotective, antidiabetic (including pancreatic β-cell regeneration), antilithiatic (anti-kidney stone), antifungal (broad-spectrum against filamentous fungi and yeast), antiviral (notably anti-HIV), antimalarial (Plasmodium falciparum inhibition in vitro/in vivo), antimicrobial (excluding bacteria), antinociceptive, and anti-lipid peroxidation properties[1][3][5]. Structure–activity studies also suggest inhibitory action on β-secretase (BACE1)[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bergenin.